Cladribine regimen for treating multiple sclerosis
US12377056B2 · kind B2 · utility
0Cited by
27References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 5, 2020 |
| Grant date | Aug 5, 2025 |
| Priority date | — |
| Expiry date | Mar 2, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/0053
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the use of multiple doses of Cladribine combined with beta interferon for the treatment of multiple sclerosis in patients who are refractory to at least one conventional therapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.